Dataset Information

Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis.

ABSTRACT:

Objectives

To assess the association of polymorphism rs198977 in the human kallikrein-2 gene (KLK2) and risk of prostate cancer (PCa).

Methods

Two investigators independently searched the PubMed, Elsevier, EMBASE, Web of Science, Wiley Online Library and Chinese National Knowledge Infrastructure (CNKI). Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) for rs198977 and PCa were calculated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate.

Results

Six studies met the inclusion criteria in this meta-analysis, which included 5859 PCa cases and 4867 controls. Overall, rs198977 was associated with the PCa risk (TT+CT vs. CC, pooled OR = 1.163, 95% CI = 1.076-1.258, P-value <0.0001). When stratified by ethnicity, significant association was observed in Caucasian samples under both allele comparison (T vs. C, pooled OR = 1.152, 95% CI = 1.079-1.229, P-value <0.0001) and dominant model (TT+CT vs. CC, pooled OR = 1.197, 95% CI = 1.104-1.297, P-value <0.0001). In the overall analysis, a comparably significant increase in the frequency of allele T for rs198977 was detected between cases and controls in Caucasian.

Conclusion

This meta-analysis suggests that rs198977 of KLK2 was associated with susceptibility of PCa in Caucasian and the allele T might increase the risk of PCa in Caucasian.

SUBMITTER: Wang L

PROVIDER: S-EPMC3688805 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Estrogen has played an important role in the development of breast cancer. ER-? PvuII gene polymorphism is in close association with the occurrence risk of breast cancer, but no consensus has been achieved currently.PubMed, Embase, China National Knowledge Infrastructure (CNKI) database, Wanfang database, and VIP database were retrieved to collect the case-control studies on association between ER? gene Pvu II polymorphism and breast cancer risk published before September 1, 2017. Newcastle-Ottawa Scale (NOS) was used to assess the quality of the literatures, Stata 14.0 software was applied for meta-analysis, and the pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated. The subgroup analysis was performed to assess the confounding factors, followed by assessment of publication bias and sensitivity analysis.A total of 26 studies were enrolled in the analysis based on inclusion criteria, which included 15,360 patients and 26,423 controls. The results demonstrated that ER? gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in 3 genetic models (C vs T, OR?=?0.962, 95% CI?=?0.933-0.992, P?=?.012; CC vs TT, OR?=?0.911, 95% CI?=?0.856-0.969, P?=?.003; CC vs TT/CT, OR?=?0.923, 95% CI?=?0.874-0.975, P?=?.004). Subgroup analysis was conducted on the basis of ethnicity and source of controls, whose results illustrated that ER? gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in Asians rather than in Caucasians (CC vs TT, OR?=?0.862, 95% CI?=?0.750-0.922, P?=?.038; CC vs TT/CT, OR?=?0.851, 95% CI?=?0.755-0.959, P?=?.008). In population-based subgroup rather than in hospital-based subgroup, ER? gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in the allele model, homozygous model, dominant model, and recessive model (C vs T, OR?=?0.943, 95% CI?=?0.911-0.977, P?=?.001; CC vs TT, OR?=?0.878, 95% CI?=?0.817-0.944, P?=?.000; CC/CT vs TT, OR?=?0.936, 95% CI?=?0.881-0.994, P?=?.031; CC vs TT/CT, OR?=?0.902, 95% CI?=?0.847-0.960, P?=?.001).ER? gene Pvu II polymorphism exerts an important function in the progression of breast cancer.